Inhibikase Therapeutics jumps after FDA lifts clinical hold on second lead drug study

Inhibikase Therapeutics

08/03/2023 14:09

** Shares of drug developer Inhibikase Therapeutics  IKT.O  jump 43.4% to
$1.01 before the bell 
    ** IKT says U.S. Food and Drug Administration has lifted clinical hold on
its second study testing its lead drug candidate, IkT-148009, as a treatment for
multiple systems atrophy (MSA)
    ** MSA is a rare disease that results in failure of autonomic nervous system
and causes impaired movement
    ** FDA's decision allows IKT to proceed with its plans for a mid-stage study
in which co will test the drug's safety, tolerability in MSA patients over 6
months 
    ** U.S. health regulator had put both studies involving IKT's lead drug on
hold in Nov. 2022 
    ** FDA recently also lifted hold on study testing the drug as a potential
treatment for Parkinson's disease  
    ** As of last close, IKT is up ~41% so far this year 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))